Clinical Research
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. May 14, 2008; 14(18): 2818-2824
Published online May 14, 2008. doi: 10.3748/wjg.14.2818
Table 4 Comparison of groups by categories n (%)
CategoriesGroup 1Group 2Group 3χ2/P
Necrosis
No change5 (35.7)12 (85.7)7 (50)χ2 = 17.20
Slight7 (50)0 (0)1 (7.1)P < 0.050
Moderate2 (14.3)2 (14.3)6 (42.9)
Regenerative activity
Slight6 (42.9)13 (92.9)6 (42.9)χ2 = 10.22
Moderate5 (35.7)1 (7.1)6 (42.9)P < 0.050
Severe3 (21.4)0 (0)2 (14.2)
Ductular proliferation
Slight0 (0)6 (42.9)1 (7.1)χ2 = 12.43
Moderate5 (35.7)5 (35.7)4 (28.6)P < 0.050
Severe9 (64.3)3 (21.4)9 (64.3)
Fibroblastic activity
Slight1 (7.1)9 (64.3)1 (7.1)χ2 = 31.06
Moderate9 (64.3)4 (28.6)11 (78.6)P < 0.001
Severe4 (28.6)1 (7.1)2 (14.3)
Kupffer cell abnormalities
Absence6 (42.9)12 (85.7)7 (50)χ2 = 6.13
Presence8 (57.1)2 (14.3)7 (50)P < 0.050
Sinusoidal congestion
Absence13 (92.9)9 (64.3)14 (100)χ2 = 8.17
Presence1 (7.1)5 (35.7)0 (0)P < 0.050
Portal central venous phlebitis
Absence3 (21.4)6 (42.9)0 (0)χ2 = 7.64
Presence11 (78.6)8 (57.1)14 (100)P < 0.050
IFN-γ (pg/mL)349.46 ± 125.15764.61 ± 191.95450.21 ± 98.25P < 0.001
IL-6 (pg/mL)839.84 ± 245.05466.5 ± 106.86710.02 ± 167.75P < 0.001